Viridian Therapeutics Stock Price on November 13, 2024

VRDN Stock  USD 19.31  0.36  1.83%   
Below is the normalized historical share price chart for Viridian Therapeutics extending back to June 18, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Viridian Therapeutics stands at 19.31, as last reported on the 26th of December, with the highest price reaching 19.44 and the lowest price hitting 18.77 during the day.
IPO Date
18th of June 2014
200 Day MA
17.3075
50 Day MA
21.6711
Beta
1.114
 
Yuan Drop
 
Covid
If you're considering investing in Viridian Stock, it is important to understand the factors that can impact its price. Viridian Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0507, which indicates the firm had a -0.0507% return per unit of risk over the last 3 months. Viridian Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Viridian Therapeutics' insignificant Risk Adjusted Performance, variance of 17.91, and Coefficient Of Variation of (8,464) to confirm the risk estimate we provide.
  
Viridian Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = -0.0507

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsVRDN

Estimated Market Risk

 4.18
  actual daily
37
63% of assets are more volatile

Expected Return

 -0.21
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.05
  actual daily
0
Most of other assets perform better
Based on monthly moving average Viridian Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viridian Therapeutics by adding Viridian Therapeutics to a well-diversified portfolio.
Price Book
2.9494
Enterprise Value Ebitda
(3.18)
Price Sales
5.1 K
Shares Float
71 M
Wall Street Target Price
40.4375

Related Headline

Fate Therapeutics Headline on 13th of November 2024

FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The companys innovative pipeline is in focus.

Viridian Therapeutics Valuation on November 13, 2024

It is possible to determine the worth of Viridian Therapeutics on a given historical date. On November 13, 2024 Viridian was worth 22.5 at the beginning of the trading date compared to the closed value of 22.48. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Viridian Therapeutics stock. Still, in general, we apply an absolute valuation method to find Viridian Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Viridian Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Viridian Therapeutics' related companies.
 Open High Low Close Volume
  27.04    27.20    22.40    22.43    4,033,094  
11/13/2024
  22.50    23.74    22.41    22.48    1,273,632  
  22.44    23.14    21.50    21.64    1,369,085  
Backtest Viridian Therapeutics  |  Viridian Therapeutics History  |  Viridian Therapeutics Valuation   PreviousNext  
Open Value
22.5
22.48
Closing Value
35.03
Upside

Viridian Therapeutics Trading Date Momentum on November 13, 2024

On November 14 2024 Viridian Therapeutics was traded for  21.64  at the closing time. The top price for the day was 23.14  and the lowest listed price was  21.50 . The trading volume for the day was 1.4 M. The trading history from November 14, 2024 was a factor to the next trading day price decrease. The trading price change against the next closing price was 3.74% . The trading price change against the current closing price is 7.07% .

Viridian Therapeutics Fundamentals Correlations and Trends

By evaluating Viridian Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Viridian Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Viridian financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Viridian Therapeutics Stock history

Viridian Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Viridian is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Viridian Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Viridian Therapeutics stock prices may prove useful in developing a viable investing in Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.

Viridian Therapeutics Quarterly Net Working Capital

544.9 Million

Viridian Therapeutics Stock Technical Analysis

Viridian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Viridian Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Viridian Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Viridian Therapeutics Period Price Range

Low
December 26, 2024
0.00  NaN%
High

 0.00 

     

 0.00 

Viridian Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Viridian Therapeutics December 26, 2024 Market Strength

Market strength indicators help investors to evaluate how Viridian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Viridian Therapeutics shares will generate the highest return on investment. By undertsting and applying Viridian Therapeutics stock market strength indicators, traders can identify Viridian Therapeutics entry and exit signals to maximize returns

Viridian Therapeutics Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Viridian Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Viridian Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Viridian to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.32)
Revenue Per Share
0.005
Quarterly Revenue Growth
0.194
Return On Assets
(0.32)
Return On Equity
(0.52)
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.